OncLive |
Galectin-1 Inhibition Shows Early Promise in Head and Neck Cancer
OncLive The carbohydrate-binding protein Galectin-1 (Gal-1) is secreted at a high level by cancer cells. Researchers at Stanford University examined whether targeted Gal-1 as part of a combinatorial approach would be effective in head and neck cancer. |
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nFumwp
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου